Robert Bruce's top dividend stocks (June 2025) include Organon & Co. (OGN), a global healthcare company focused on women's health.

Robert Bruce is known as an astute investor who focuses on dividend-paying stocks. He is an investment manager who carefully selects companies for his portfolio, focusing on long-term value and income generation. His investment decisions reflect a strategy of identifying companies with consistent dividend payouts.

Organon & Co. (ogn)

Organon & Co. is a global healthcare company with a focus on women's health, biosimilars, and established brands. The company develops and markets therapies across a range of reproductive health, heart disease, skin and allergy conditions, and respiratory diseases. Currently, Robert Bruce's portfolio holds a $287.66K position in Organon & Co. The company’s TTM dividend rate is $0.86, and it boasts a dividend yield of 9.33%. The discounted cash flow value is $28.33, and the analyst price target is $14.0.

Here's an overview of Robert Bruce's trades in Organon & Co.: [STOCKCIRCLE_EMBED_PLACEHOLDER_ogn]

Chemours Company (cc)

Chemours Company is a leading provider of performance chemicals. Their products serve industries such as automotive, construction, electronics, and general industrial markets. Robert Bruce's current portfolio includes $2.03M worth of Chemours shares. The dividend yield for Chemours is currently 8.27%, with a TTM dividend rate of $0.84. The analyst price target for Chemours is $16.0, but the discounted cash flow value is -$2.55.

Here's an overview of Robert Bruce's trades in Chemours Company: [STOCKCIRCLE_EMBED_PLACEHOLDER_cc]

Pfizer Inc. (pfe)

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and markets vaccines and medicines. Their extensive portfolio includes innovative therapies and established treatments across a broad range of medical fields. Robert Bruce's position in Pfizer is valued at $6.39M. Pfizer offers a dividend yield of 7.24%, and the TTM dividend rate stands at $1.70. The analyst price target for Pfizer is $24.0, and the discounted cash flow value is $64.3.

Here's an overview of Robert Bruce's trades in Pfizer Inc.: [STOCKCIRCLE_EMBED_PLACEHOLDER_pfe]

RLI Corp. (rli)

RLI Corp. is a specialty insurance company that offers a variety of property and casualty coverages. Their products are available throughout the United States, focusing on niche markets and underserved segments. The current value of Robert Bruce's holdings in RLI Corp. is $3.14M. RLI Corp. has a dividend yield of 6.74% and a TTM dividend rate of $5.02. The discounted cash flow value is $191.25.

Here's an overview of Robert Bruce's trades in RLI Corp.: [STOCKCIRCLE_EMBED_PLACEHOLDER_rli]

Viatris Inc (vtrs)

Viatris Inc. is a global pharmaceutical company that produces and markets a diverse portfolio of branded and generic medications. Their products span a wide range of therapeutic areas. Robert Bruce's investment in Viatris is currently valued at $512.27K. The dividend yield for Viatris is 5.46%, and its TTM dividend rate is $0.48. The discounted cash flow value is $34.51.

Here's an overview of Robert Bruce's trades in Viatris Inc: [STOCKCIRCLE_EMBED_PLACEHOLDER_vtrs]